As Greek yogurt’s popularity soared, Yoplait struggled to market its own version. Then it decided to develop something else: a compelling story.
NYS Entity Status
NYS Filing Date
JANUARY 16, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2014 - GRIFFIN BLADE MANUFACTURING, INC.
Around the Web
- Adventures in Capitalism: Yoplait Learns to Manufacture Authenticity to Go With Its Yogurt
By CHARLES DUHIGG - Monday Jun 26, 2017
- Shot-tracking systems churn out valuable data for golfers, manufacturers
By David Dusek - Tuesday Oct 17, 2017
On the Tuesday before the Presidents Cup at the posh Fenway Golf Club in Scarsdale, N.Y., TaylorMade announced it has partnered with Samsung (...)
- Jail Escape Plan: Blankets? Check. Floss. You Bet. But a Priest?
By MATT STEVENS - Thursday Sep 14, 2017
Prosecutors said Christopher Londonio had a plan to use dental floss to cut a window, sheets as a rope — and a priest to smuggle in a saw blade.
- Qualcomm files lawsuits in China to ban iPhones
By Reuters - Saturday Oct 14, 2017
(Reuters) — Qualcomm Inc confirmed an earlier report that the chipmaker had filed lawsuits in China, seeking to halt the manufacture and sale of Apple Inc’s iPhones in the country. Qualcomm filed the suits in a Beijing intellectual property court, claiming patent infringement and is seeking injunctive relief, a company spokeswoman confirmed on Friday, but […]
- Trump says Apple CEO has promised to build three manufacturing plants in U.S.
By Tripp Mickle and Peter Nicholas - Wednesday Jul 26, 2017
President Donald Trump on Tuesday said in an interview that Apple Inc. Chief Executive Tim Cook has committed to build three big manufacturing plants in the U.S., a surprising statement that would help fulfill his administration’s economic goal of reviving American manufacturing.
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.